Brokerages expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to post ($0.13) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aptose Biosciences’ earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.12). Aptose Biosciences posted earnings per share of ($0.17) during the same quarter last year, which would suggest a positive year over year growth rate of 23.5%. The business is expected to announce its next quarterly earnings report on Tuesday, March 10th.

According to Zacks, analysts expect that Aptose Biosciences will report full-year earnings of ($0.53) per share for the current year, with EPS estimates ranging from ($0.55) to ($0.51). For the next year, analysts forecast that the business will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.70) to ($0.55). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01.

Several analysts recently issued reports on the stock. ValuEngine cut shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a report on Monday. HC Wainwright cut their price target on shares of Aptose Biosciences from $8.50 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Finally, Zacks Investment Research cut shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Aptose Biosciences has an average rating of “Buy” and an average price target of $5.25.

Several large investors have recently modified their holdings of the business. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Aptose Biosciences by 7.9% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 85,029 shares of the biotechnology company’s stock valued at $221,000 after acquiring an additional 6,200 shares during the period. Sigma Planning Corp boosted its holdings in shares of Aptose Biosciences by 4.1% in the 3rd quarter. Sigma Planning Corp now owns 228,150 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 9,000 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Aptose Biosciences by 20.7% in the 2nd quarter. Morgan Stanley now owns 315,521 shares of the biotechnology company’s stock worth $824,000 after purchasing an additional 54,200 shares in the last quarter. Gagnon Securities LLC purchased a new position in shares of Aptose Biosciences in the 2nd quarter worth about $146,000. Finally, Creative Planning purchased a new position in shares of Aptose Biosciences in the 3rd quarter worth about $156,000. 22.55% of the stock is currently owned by institutional investors.

APTO traded down $0.08 during trading on Tuesday, hitting $2.38. The company had a trading volume of 180,100 shares, compared to its average volume of 310,872. The company has a market cap of $137.05 million, a PE ratio of -2.77 and a beta of 1.64. The business has a 50-day moving average of $2.13 and a 200-day moving average of $2.29. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.83 and a quick ratio of 7.83. Aptose Biosciences has a 1-year low of $1.57 and a 1-year high of $3.13.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Story: Limitations of analyzing profit margin

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.